Sodium bicarbonate, anhydrous citric acid, anhydrous sodium citrate, tartaric acid.
Each sachet of 4-g effervescent granules contains sodium bicarbonate 1.76 g, anhydrous citric acid 0.72 g, anhydrous sodium citrate 0.63 g, tartaric acid 0.89 g. It also contains natural lemon oil flavour and saccharin sodium.
Systemic and urinary alkalization where indicated in the relief of symptoms associated with urinary tract infections.
Adult: Add the contents of 1-2 sachets to a glass of cool water and mix. Ural may be taken up to 4 times daily. Do not take for >5 days unless advised to do so by the physician.
Overdosage may result in metabolic alkalosis. Ural should be discontinued, appropriate treatment instituted and electrolyte and acid-base determinations should be carried out as appropriate.
Renal failure or hypernatremia; in conjunction with hexamine mandelate or hexamine hippurate therapy because an acidic urine is needed. Caution is advised in overt and occult cardiac failure. Concomitant use of urinary alkalinisers and quinolone antibiotics should be avoided; crystalluria may be more likely to occur in alkaline urine.
Ural contains sodium 650 mg/sachet which should be taken into account by those on a low sodium diet. Patients should be advised to consult a doctor if pain or irritation persists for >48 hrs or if blood is noticed in their urine. Ural should be used cautiously in patients with cardiac failure, hypertension, impaired renal function, peripheral and pulmonary oedema and preeclampsia. The clinical condition of the patient should be evaluated and laboratory determinations (eg. serum electrolytes, acid-base balance) obtained periodically during Ural therapy, particularly in patients with renal disease.
Use in pregnancy & lactation: Studies regarding the effect of citrates on pregnancy have not been done. Caution should be exercised when administered to a nursing mother.
Use in children: Do not give Ural to children <12 years unless advised to do so by a doctor.
Studies regarding the effect of citrates on pregnancy have not been done. Caution should be exercised when administered to a nursing mother.
The tartrate component of Ural may be incompletely absorbed. Because of this Ural may be exert a mild laxative effect. Prolonged and excessive use may cause a systemic alkolosis and/or hypernatremia.
Alkalinization of the urine due to the use of Ural, theoretically, may result in a decreased therapeutic effect of the following medications, chlorpropemide, lithium, salicylates and tetracyclines. Alternatively, alkalinization of the urine due to the use of Ural, theoretically, may result in an increased therapeutic effect of the following medications, amphetamines and ephedrine/pseudoepherine.
Antacid: Concomitant use of antacids with citrates may result in systemic alkalosis. Concurrent use of antacids with sodium citrate and sodium bicarbonate may promote the development of calcium stones in patients with uric acid stones and may also cause hypernatremia.
Concurrent use of aluminium-containing antacids with citrate salts can increase aluminium absorption, possibly resulting in acute aluminium toxicity, especially in
patients with renal insufficiency.
Quinolones: Citrates may reduce the solubility of ciprofloxacin, norfloxacin, or ofloxacin in the urine. Patients should be observed for signs of crystalluria and nephrotoxicity.
Laxatives: Concurrent administration of citrates with laxatives may have an additive effect.
Store at temperature below 30°C.
Shelf-Life: 36 months
G04BX - Other urologicals ; Used in the treatment of urological problems.
Effervescent granules (sachet) 4 g x 28's.